Finance

Lists
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$33.07
-1.61%
(-0.54) 1D
$32.42
-1.96% (-0.65)
After hours
Closed: Sep 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Open
$33.29
High
$33.40
Low
$32.77
Mkt. cap
1.97B
Avg. vol.
926.77K
Volume
1.57M
52-wk high
$45.99
52-wk low
$22.24
EPS
-$7.01
Beta
0.60
Shares outstanding
59.70M
No. of employees
540
Open
$33.29
High
$33.40
Low
$32.77
Mkt. cap
1.97B
Avg. vol.
926.77K
Volume
1.57M
52-wk high
$45.99
52-wk low
$22.24
EPS
-$7.01
Beta
0.60
Shares outstanding
59.70M
No. of employees
540
News stories
From web sources and news partners
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorBiotechnology
Websiteagios.com
Analyst ratings
Based on 8 analysts giving stock ratings to AGIO in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for AGIO in the last 3 months.
Highest
Current $33.07
$55.00 (+66.31%)
Average
$43.40 (+31.24%)
Lowest
$32.00 (-3.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gregory Renza
Truist Financial
Buy
Maintained
-
-
08/11/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/03/2026
Luca Issi
RBC Capital
Hold
Maintained
$32.00
-3.2%
07/30/2026
Samantha Semenkow
Citi
Buy
Maintained
$52.00
+57.2%
07/31/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$46.00
+39.1%
07/30/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$55.00
+66.3%
07/30/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$32.00
-3.2%
07/21/2026
Andrew Berens
Leerink Partners
Buy
Maintained
-
-
07/07/2026
Tessa Romero
J.P. Morgan
Hold
Reiterated
$31.00
-6.3%
06/11/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.69 / -$1.66
-1.50%miss
Revenue / Est. (USD)
44.74M / 26.70M
+67.55%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.88M
19.97M
20.75M
44.74M
Cost of goods sold
88.48M
89.94M
82.47M
103.75M
Cost of revenue
88.48M
89.94M
82.47M
103.75M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41.27M
51.61M
48.30M
51.55M
Operating expense
41.27M
51.61M
48.30M
51.55M
Total operating expenses
129.75M
141.54M
130.77M
155.30M
Operating income
-116.87M
-121.58M
-110.02M
-110.55M
Other non operating income
67.00K
113.00K
119.00K
119.00K
EBT including unusual items
-103.43M
-109.06M
-99.11M
-100.70M
EBT excluding unusual items
-103.43M
-109.06M
-99.11M
-100.70M
Income tax expense
-
-1.02M
-
-
Effective tax rate
-
0.93%
-
-
Other operating expenses
-
-
-
-
Net income
-103.43M
-108.04M
-99.11M
-100.70M
Net profit margin
-803.05%
-541.09%
-477.74%
-225.06%
Earnings per share
-1.78
-1.85
-1.69
-1.69
Interest and investment income
13.37M
12.41M
10.80M
9.73M
Interest expense
-
-
-
-
Net interest expenses
13.37M
12.41M
10.80M
9.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
-115.50M
-120.31M
-108.66M
-109.20M
Gain or loss from assets sale
299.00K
-299.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps